行情

PRTA

PRTA

Prothena Corp
NASDAQ

实时行情|Nasdaq Last Sale

11.51
+0.52
+4.73%
已收盘, 17:10 04/02 EDT
开盘
10.97
昨收
10.99
最高
11.62
最低
10.51
成交量
23.31万
成交额
--
52周最高
17.63
52周最低
6.71
市值
4.59亿
市盈率(TTM)
-5.9098
分时
5日
1月
3月
1年
5年

分析师评级

8位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测PRTA价格均价为14.50,最高价位19.00,最低价为13.00。

EPS

PRTA 新闻

更多
  • Baseline Data from Phase 2 PASADENA Study of Prasinezumab (PRX002/RG7935) in Parkinsons Disease to be Presented at AAT-AD/PD
  • GlobeNewswire · 2天前
  • Prothena Reports Baseline Data From Phase 2 PASADENA Study Of Prasinezumab In Patients With Early Parkinson's Disease Will Be Presented By Roche
  • Benzinga · 2天前
  • Prothena (PRTA) Down 24.8% Since Last Earnings Report: Can It Rebound?
  • Zacks · 03/13 16:30
  • Prothena Announces Appointment of Brandon Smith as Chief Business Officer
  • GlobeNewswire · 03/03 21:05

所属板块

生物技术和医学研究
+3.33%
制药与医学研究
+2.80%

热门股票

代码
价格
涨跌幅

PRTA 简况

Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004). The Company has generated monoclonal antibodies that selectively bind to amyloidogenic (diseased) forms of the Transthyretin (TTR)-mediated amyloidosis (ATTR) protein. The Company's pipeline also includes late discovery-stage programs for which the Company is testing the efficacy of antibodies in preclinical models of diseases related to amyloid or cell adhesion.
展开

微牛提供Prothena Corporation PLC(NASDAQ-PRTA)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的PRTA股票新闻,以帮助您做出投资决策。